Abstract
A long term follow-up study has been undertaken in 33 patients with acute non-lymphoblastic leukaemia (ANLL) in order to establish whether a correlation exists between the clinical course and the immunologic pattern of lymphoid subpopulations. Peripheral blood lymphoid cells have been investigated longitudinally (each 1 to 4 months) during complete remission (CR), by morphologic, phenotypic and functional analyses. Particular attention has been paid to the evaluation of the natural killer (NK) cell compartment, by the detection of cells expressing an NK-related phenotype and by NK in vitro assay. Among the patients so far evaluable, 20 relapsed (R) and 10 are long survivors in CR 'off therapy' (LS). The most relevant finding was represented by statistically higher values of NK activity observed in LS vs. R patients (P less than 0.01). The removal of adherent cells before the NK assay, performed to investigate the possible inhibitory effect on NK function played by the macrophage component, abolished this difference, due to a selective increase of NK function in the R group. The longitudinal study revealed that NK activity tended to decrease in individual patients who subsequently relapsed. These data suggest a possible role of NK cells in the relapse control of ANLL, although it cannot be excluded that the low level of NK activity observed in the R group is the result of impending relapse rather than its cause.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pizzolo, G., Trentin, L., Vinante, F. et al. Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. Br J Cancer 58, 368–372 (1988). https://doi.org/10.1038/bjc.1988.221
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.221
This article is cited by
-
Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia
Cancer Immunology, Immunotherapy (2023)
-
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Stem Cell Research & Therapy (2021)
-
Natural killer cell immune escape in acute myeloid leukemia
Leukemia (2012)
-
Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation
Bone Marrow Transplantation (2000)
-
Acute Leukaemia
Clinical Immunotherapeutics (1996)